HBIO logo

Harvard Bioscience Inc. (HBIO)

$9.08

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on HBIO

Market cap

$41523566

EPS

-2.59

P/E ratio

--

Price to sales

0.43

Dividend yield

--

Beta

1.4769

Price on HBIO

Previous close

$8.91

Today's open

$9

Day's range

$8.83 - $9.58

52 week range

$4 - $10.20

Profile about HBIO

CEO

John Duke

Employees

339

Headquarters

Holliston, MA

Exchange

NASDAQ Capital Market

Shares outstanding

4573080

Issue type

Common Stock

HBIO industries and sectors

Healthcare

Biotechnology & Life Sciences

News on HBIO

Harvard Bioscience, Inc. (HBIO) Q3 2026 Earnings Call Transcript

Harvard Bioscience, Inc. (HBIO) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 10, 2026

news preview

Harvard Bioscience Announces Third Quarter 2026 Financial Results

Third Quarter 2026 Revenue Growth of 8% Year Over Year to $22.2 Million  Reaffirms Full Year 2026 Revenue Guidance of 3%-5% Year Over Year Growth HOLLISTON, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced financial results for the third quarter ended September 30, 2026.

news source

GlobeNewsWire • Nov 10, 2026

news preview

Harvard Bioscience to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum

HOLLISTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Chief Financial Officer, will participate in Canaccord Genuity's MedTech, Diagnostics, and Digital Health and Services Forum on November 11th, 2026.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Harvard Bioscience Schedules Third Quarter 2026 Earnings Conference Call for November 10, 2026 at 8:00 AM ET

HOLLISTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2026, before the market opens on November 10, 2026, and will hold a conference call to discuss the results at 8:00 a.m.

news source

GlobeNewsWire • Oct 27, 2026

news preview

Harvard Bioscience Announces Creation of Scientific Advisory Board

HOLLISTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced the creation of its Scientific Advisory Board (SAB) to guide the Company's ongoing research, development, and new product roadmaps.

news source

GlobeNewsWire • Oct 6, 2026

news preview

Harvard Bioscience, Inc. (HBIO) Q2 2026 Earnings Call Transcript

Harvard Bioscience, Inc. (HBIO) Q2 2026 Earnings Call Transcript

news source

Seeking Alpha • Aug 11, 2026

news preview

Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET

HOLLISTON, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2026, before the market opens on August 11, 2026, and will hold a conference call to discuss the results at 8:00 a.m.

news source

GlobeNewsWire • Jul 28, 2026

news preview

Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript

Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript

news source

Seeking Alpha • May 12, 2026

news preview

Harvard Bioscience Announces First Quarter 2026 Financial Results

First Quarter 2026 Revenues of $20.8M and Gross Margin of 59% Consolidation of Manufacturing Operations Progressing on Schedule Reaffirms Full Year 2026 Financial Guidance HOLLISTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced financial results for the first quarter ended March 31, 2026.

news source

GlobeNewsWire • May 12, 2026

news preview

Harvard Bioscience to Participate in Upcoming Investor Conferences

HOLLISTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced Chief Executive Officer, John Duke and Chief Financial Officer, Mark Frost's participation in the following upcoming investor events.

news source

GlobeNewsWire • May 7, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Harvard Bioscience Inc.

Open an M1 investment account to buy and sell Harvard Bioscience Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in HBIO on M1